Tirzepatide Options Online: What Patients Should Know

Published June 29, 2026

Mounjaro vs Zepbound vs Compounded Tirzepatide

All three contain tirzepatide — but they are not interchangeable products. Mounjaro (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg weekly) is FDA-approved for type 2 diabetes. Zepbound (same dose range) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

Patients commonly search 'Mounjaro for weight loss' because it was one of the first widely-discussed tirzepatide products, but Zepbound is the labeled weight management indication. Compounded tirzepatide is not FDA-approved and is not generic Mounjaro or Zepbound — the most important thing any provider can say about this product.

The SURMOUNT-1 trial (NEJM 2022) established tirzepatide's efficacy: 20.9% mean weight loss at the 15mg dose over 72 weeks in adults with obesity or overweight without diabetes. The SURPASS-2 trial (NEJM 2021) found tirzepatide produced greater HbA1c reduction and body weight reduction than semaglutide 1mg in patients with type 2 diabetes.

What Online Mounjaro Prescribing Actually Means

Online prescribing of Mounjaro is possible when a licensed provider reviews the patient's medical history and determines the medication is clinically appropriate for their specific diagnosis (typically type 2 diabetes). A provider who prescribes Mounjaro for weight loss in a patient without type 2 diabetes is making an off-label prescribing decision.

For patients seeking tirzepatide specifically for weight management — without a type 2 diabetes diagnosis — the more appropriate pathways are: Zepbound through insurance or a manufacturer direct-pay program (LillyDirect), or compounded tirzepatide through a licensed cash-pay telehealth provider after individual provider review.

Key Comparison Table

Question	Mounjaro	Zepbound	Compounded tirzepatide
FDA-approved for	Type 2 diabetes	Chronic weight management + CV risk reduction	Not FDA-approved for any indication
FDA approval date	May 2022	November 2023	N/A — not FDA-approved
Insurance coverage (weight loss)	Generally not covered for weight loss	Varies by plan — prior auth often required	Usually cash-pay only
Cash price without insurance	$1,000+/month at retail	$299/month via LillyDirect at the 2.5mg starter dose	$125/month at Ozari for eligible patients
Can be prescribed online?	Yes — with licensed provider review for appropriate indication	Yes — with licensed provider review	Yes — through licensed telehealth platform after provider review
Generic available?	No — no generic tirzepatide exists	No — no generic Zepbound exists	Not generic — compounded versions are not generics

Red Flags — Avoid These Providers

Frequently Asked Questions

Can Mounjaro be prescribed online?

Yes — online prescribing can be appropriate when a licensed provider reviews the patient and determines Mounjaro is clinically appropriate for their specific diagnosis. Mounjaro is FDA-labeled for type 2 diabetes.

Is Mounjaro approved for weight loss?

Mounjaro is FDA-approved for type 2 diabetes management, not for weight loss. Zepbound is the tirzepatide product approved for chronic weight management.

Is compounded tirzepatide the same as Mounjaro?

No. Compounded tirzepatide is not FDA-approved and is not generic Mounjaro. Both contain tirzepatide as the active ingredient when properly sourced, but they have fundamentally different regulatory status.

How much does Mounjaro cost without insurance?

Mounjaro's retail price without insurance typically exceeds $1,000/month. Insurance coverage depends on the patient's plan and type 2 diabetes diagnosis. LillyDirect does not currently offer Mounjaro self-pay — verify directly.

Does Ozari offer tirzepatide treatment online?

Yes. Ozari offers online provider review for tirzepatide-based treatment. Compounded tirzepatide starts at $125/month for eligible starter-plan patients after licensed provider review.

What is the cheapest tirzepatide option?

Compounded tirzepatide through a licensed cash-pay telehealth provider is typically the lowest-cost option. Ozari lists compounded tirzepatide from $125/month for eligible starter-plan patients. Branded Zepbound through LillyDirect currently starts at $299/month for the 2.5mg starter dose under Lilly's self-pay terms.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Clinical trial results for FDA-approved products should not be extrapolated as guaranteed outcomes for compounded medications. Individual results vary. Always consult a licensed healthcare provider before starting any prescription medication. Ozari Health is a telehealth platform that connects patients with licensed, independent healthcare providers.

Sources

FDA label — Mounjaro tirzepatide injection: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0

FDA — Zepbound approval for chronic weight management: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management

SURMOUNT-1 tirzepatide trial (NEJM): https://pubmed.ncbi.nlm.nih.gov/35618545/

SURPASS-2 tirzepatide vs semaglutide (NEJM): https://pubmed.ncbi.nlm.nih.gov/34170647/

FDA — Concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Ozari Health tirzepatide pricing: https://www.ozarihealth.com/treatments/tirzepatide

treatment